Study guides / Series 79: Investment Banking Representative / Research, syndicate & internal communications
Research, syndicate & internal communications
Series 79: Investment Banking Representative · quick review
Who a banker may talk to, and about what: clients, research, the syndicate desk, and legal and compliance. How information barriers work, and the FINRA Rule 2241 limits that keep research independent of investment banking.
The rules
- Two sides of the wall: bankers work on the private side with material nonpublic information (MNPI); sales, trading and research work on the public side. Exchange Act Section 15(g) requires every broker-dealer to keep and enforce written policies reasonably designed to stop its misuse. Firms use information barriers, watch and restricted lists, and wall crossings approved by compliance.
- Clients and Regulation FD: analysts gather and check model inputs with management, usually under a confidentiality agreement. Regulation FD excludes disclosure to someone who owes the issuer a duty of trust or confidence (such as an investment banker, lawyer or accountant) or who expressly agrees to keep the information confidential. But if an issuer gives MNPI to broker-dealers, advisers, funds or holders likely to trade on it, it must go public at the same time (intentional) or promptly (non-intentional): by the later of 24 hours or the next NYSE open after a senior official learns of it.
- Syndicate desk, specialists and compliance: the syndicate desk tells bankers what’s in the market: live deals, investor demand, pricing, structure and covenants. Industry and product specialists supply sector data, deal ideas and views on the best marketing approach. Internal departments review data going into marketing materials, and legal and compliance approve those materials and are the first call whenever a conversation might cross the wall.
- Research independence (Rule 2241): bankers may not review, clear or approve research before publication, supervise analysts or influence their pay. Analyst pay can’t be tied to specific deals or to contributions to banking. Research management makes the final coverage decisions, only senior management outside banking sets the research budget, and retaliation over negative research is banned. Information barriers must also shield analysts from pressure by sales and trading.
- No selling by analysts: analysts may not join pitches or other solicitations of banking business, or road shows and other marketing for a deal, and bankers may not direct them to market a deal or talk to customers about one. Pitch materials may state the fact of coverage and the analyst’s name, but nothing suggesting favorable research. Promising favorable research in exchange for business is banned.
- Due diligence and three-way meetings: analysts may not do due diligence in the presence of bankers before the issuer selects its underwriters. An analyst may never discuss a deal with a current or prospective customer while bankers or company management are present. Anything an analyst says about a deal to customers or internal staff must be fair, balanced and not misleading.
- Consulting research: contact isn’t banned outright. Bankers may ask analysts for market, sector and valuation views, within firm safeguards (often a compliance chaperone). But under FINRA staff guidance a banker may not present a valuation to an issuer as the analyst’s own or as a joint view, and solicitation-period contact carries elevated risk.
- Quiet periods (minimums): no research reports or analyst public appearances on the issuer for 10 days after an IPO, for any firm that was an underwriter or dealer, and 3 days after a secondary offering, for managers and co-managers. Exceptions: significant news or events with prior legal or compliance approval, and Rule 139 reports on actively traded securities during the secondary period.
- Emerging growth companies (EGCs): the JOBS Act eases these limits. No quiet period follows an EGC’s IPO or secondary offering; analysts may attend an EGC IPO pitch meeting with bankers but may not solicit business there; and FINRA doesn’t apply the joint due diligence ban to EGC management meetings attended by both.
- What research reports disclose: the firm’s ownership of 1% or more of any class of the company’s common equity; deals managed or banking pay received in the past 12 months, and banking pay expected or sought in the next 3 months; and the analyst’s holdings. Under Regulation AC the analyst also certifies that the views are his or her own and says whether pay is tied to them.
Common traps
- Legal and compliance may review research before publication; bankers may never review, clear or approve it.
- Quiet periods: 10 days after an IPO for every underwriter or dealer, 3 days after a secondary offering for managers and co-managers only, and none for an EGC.
- Analysts may watch a road show remotely or from another room, but may not take part in it.
- An analyst may attend an EGC IPO pitch, but soliciting the business is still prohibited.
- Giving MNPI to the issuer’s banker isn’t a Regulation FD problem. Giving it to a portfolio manager is, unless the manager expressly agrees to keep it confidential.
How it's tested
Deciding whether a contact is allowed (banker to analyst, analyst to customer, issuer to investor), quiet period lengths and whom they bind, and what Rule 2241 requires firms to wall off or disclose.
Practise it
The full lesson, worked examples and practice questions are in Tickmark, where every answer choice is explained.
Open the full lesson